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CIntroduction: When health state utility values for comorbid health
onditions are not available, data from cohorts with single conditions
re used to estimate scores. The methods used can produce very dif-
erent results and there is currently no consensus onwhich is themost
ppropriate approach. Objective: The objective of the current study
as to compare the accuracy of five differentmethodswithin the same
ataset. Method: Data collected during five Welsh Health Surveys
ere subgrouped by health status. Mean short-form 6 dimension (SF-
D) scores for cohorts with a specific health condition were used to
stimate mean SF-6D scores for cohorts with comorbid conditions
sing the additive, multiplicative, and minimum methods, the ad-
usted decrement estimator (ADE), and a linear regression model.
esults: The mean SF-6D for subgroups with comorbid health condi-
ions ranged from 0.4648 to 0.6068. The linearmodel produced themost
ccurate scores for the comorbid health conditions with 88% of values O
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al So
oi:10.1016/j.jval.2010.12.011ccurate to within theminimum important difference for the SF-6D. The
dditive and minimum methods underestimated or overestimated the
ctual SF-6D scores respectively. The multiplicative and ADE methods
oth underestimated themajority of scores. However, bothmethods per-
ormed better when estimating scores smaller than 0.50. Although the
ange inactualhealth stateutility values (HSUVs)was relatively small, our
ata covered the lower end of the index and the majority of previous
esearch has involved actual HSUVs at the upper end of possible ranges.
onclusions: Although the linear model gave the most accurate re-
ults in our data, additional research is required to validate our find-
ngs.
eywords: health-related quality of life, health state utility, methodol-
gy, SF-6D, utility.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Policy decision makers such as the National Institute for Health
and Clinical Excellence (NICE) in the United Kingdom recommend
that the results of economic evaluations in health care are pre-
sented in terms of quality adjusted life years (QALY) [1]. The QALY
quantifies both health-related quality of life and life expectancy in
a single metric and allows comparison across disparate diseases
and interventions [2]. The health state utility values (HSUVs) used
to weight the QALYs are obtained from preference-based mea-
sures of health, such as the EuroQol five-dimensional (EQ-5D)
questionnaire and the short-form 6 dimension (SF-6D) [3,4].
Although there is a large evidence base for HSUVs associated
with single health conditions, due to the large number of possible
combinations of health conditions, studies reporting HSUVs for
comorbid health conditions are limited. When these data are not
available, HSUVs for comorbid health conditions are estimated
using the HSUVs obtained from people with single conditions. For
example, the mean HSUV for a comorbid health condition defined
as both condition A and condition B would be estimated using the
meanHSUVs obtained from cohortswith condition A (but not con-
dition B) and the mean HSUV from cohorts with condition B (but
not condition A). The three most frequently used techniques are
the additive, multiplicative, and minimummethods. The additive
* Address correspondence to: Roberta Ara, Health Economics and D
heffield S1 4DA, UK.
E-mail: r.m.ara@sheffield.ac.uk.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.and multiplicative methods assume a constant absolute or con-
stant proportional decrement respectively whereas the minimum
method attributes no additional health decrement, taking the
smallest HSUV from the single health conditions involved.
The evidence base describing empirical research in this area is
limited and there is currently no consensus on themost appropri-
ate approach. The multiplicative method gave a good fit on HUI3
data from the Canadian Community Health Survey [5]; and was
more accurate than the additive method on EQ-5D data from the
Medical Expenditure Panel Survey (MEPS) [6]. The minimum
method performed better than both the additive and the multipli-
cative methods on EQ-5D data from the MEPS [7]. More recently, a
variation of the minimum method, the adjusted decrement esti-
mator (ADE), has been proposed andwas shown to outperform the
three other methods on EQ-5D data from MEPS [8].
Themethods can produce very different HSUVs and it has been
eported that these differences are great enough to potentially
nfluence a policy decision based on a cost per QALY threshold [9].
his undermines the rationale for consistent reimbursement rec-
mmendations and optimal resource allocation. The objective of
he current study was to assess the accuracy of all four methods
sing SF-6D data collected in the Welsh Health Surveys. These
esults were also compared to values predicted using a parametric
odel that maps from mean HSUVs obtained from cohorts with
ion Science, ScHARR, The University of Sheffield, 30 Regent Street,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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741V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 4 0 – 7 4 5single health conditions onto HSUVs for cohorts with comorbid
health conditions.
Methods
Welsh health survey dataset
TheWelsh health survey (WHS) is an annual survey, which draws
from a random sample of the population living in private house-
holds in Wales [10-14]. Responses collected during the surveys
conducted in the years 2003, 2004, 2005, 2007, and 2008 were
pooled for use in the current study. HSUVs were obtained using
the SF-6D (v2) preference-based measure which is derived from
responses to the SF-36 generic health questionnaire [15]. The
SF-6D is a six-dimensional health state classification system as-
sessing physical functioning, role-limitations, social functioning,
pain, mental health, and vitality. The classification system gener-
ates a total of 18,000 possible health states. Weights for the SF-6D
preference-measure used in the current studywere obtained from
a random sample of the UK general population using anchors of
zero and one to represent death andperfect health respectively [3].
The SF-6D is scored on a continuous index whereby 0.296 repre-
sents the maximum impaired level on all six dimensions and 1
represents the least impaired level.
In addition to questions on health related quality of life,
respondents were asked to indicate if they had any limiting
long-term health conditions. The coded data provide informa-
tion on 39 individually categorized and 14 grouped limiting
long-term health conditions (see online Appendix A found at
doi:10.1016/j.jval.2010.12.011). All analyses were weighted us-
ing the individual level self-administered questionnaire
weights that adjust for non response.
Methods used to estimate HSUVs
The “actual” mean SF-6D scores were calculated for subgroups (n
 30) of respondents with comorbid pairs of health conditions
(condition A and condition B), and for subgroups with condition A
(and not condition B) or condition B (and not condition A). The
latter were then used to estimate mean SF-6D scores for the co-
horts with comorbid health conditions using the three frequently
used (additive, minimum, and multiplicative) methods and the
ADE. In addition, the relationship between the SF-6D scores from
cohorts with single health conditions and the SF-6D scores from
cohorts with combined conditions was also explored using ordi-
nary least square regression (OLS). Details of the five methods
compared are provided below.
For the two health conditions, condition A and condition B, the
following combinations are possible: condition A and condition B;
neither condition A nor condition B; condition A, but not condition
B; condition B, but not condition A. The HSUVs associated with
these alternatives are defined to beUA,B, UnA,nB, UA, andUB, respec-
tively.
The additive method assumes a constant absolute detriment
relative to the baseline. When assuming a baseline of full health
the additive method is written as:
UA, B
add  1 1U1 1UB (1)
Using an adjusted baseline (see next section) the additive method
is written as:
UA, B
add  UnA, nB UnAUA UnbUB (2)
The multiplicative method assumes a constant proportional
detriment relative to the baseline. When assuming a baseline of
full health, the multiplicative method is written as:UA, B
multUA ·UB (3) pWhen using an adjusted baseline, the multiplicative method is
written as:
UA, B
mult  UnA, nB · UAUnA · UBUnB (4)
The minimum method assumes the impact on health-related
uality of life (HRQoL) for a comorbid health condition is equiva-
ent to the most severe of the single health conditions. For exam-
le, there is no additional decrement associated with a second
ealth condition. When assuming a baseline of full health, the
inimum method is written as:
A, B
minminUA,UB (5)
hen using an adjusted baseline, theminimummethod iswritten
s:
A, B
minminUnA, nB, UA, UB (6)
The adjusted decrement estimator (ADE) proposed by Hu [8],
ssumes the HSUV for the comorbid health condition is bound by
heminimumHSUV of the two HSUVs for the single health condi-
ions and is written as:
A, B
ADEminUA, UBminUA, UB · 1UA · 1UB (7)
In addition to the methods described above, a simple linear
odel has been proposed [16]. Based on decision theory, multi-
ttribute utility functions [17,18], and a prospect theory [19] the
odel incorporates terms that represent the additive, multiplica-
ive and minimum methods [16]. The model is defined by:
A, B
comb01 ·min1UA, 1UB2 ·max1UA,
1UB3 · UA ·UB (8)
whereby the beta coefficients are obtained using ordinary least
square regressions and  represents the residual. We use the fol-
owing adaptation which incorporates an adjusted baseline:
A, B
comb01 ·minUnAUA, UnbUB2 ·maxUnAUA,
UnbUB3 ·UnA, nB · UAUnA · UBUnb (9)
When using a baseline of full health it is assumed that if a
particular health condition is alleviated, the HSUV for the health
condition will revert to 1 on a preference based utility index. This
assumption, however, ignores the natural decline in health due to
age and additional comorbidities and overestimates the decre-
ment on health-related quality of life associated with health con-
ditions [20]. Consequently this may not be the most appropriate
technique when estimating HSUVs for comorbid health condi-
tions. Several alternatives have been suggested and these in-
clude: “purifying” data by dividing all HSUVs by the mean HSUV
obtained from individuals with none of the health conditions
[5], or using HSUVs associated with not having specific health
conditions [6]. We used age adjusted baseline HSUVs obtained
rom respondents who do not have any of the health conditions
dentified in the WHS.
The methods used to estimate HSUVs for the combined health
onditions were assessed in terms of errors (actual minus esti-
ated) in the estimated HSUVs. In addition to the statistics gen-
rally reported (mean absolute errors [MAE], mean squared errors
MSE], and root mean squared error [RMSE]), the proportion of
rrors within the minimum important difference (MID) for the
F-6D (MID  0.041) [21] were calculated and the magnitude of
rrors across the actual SF-6D scores were examined using scatter
lots.
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The pooled data included 64,437 cases with SF-6D scores. The
mean SF-6D for the full sample irrespective of health status was
0.7613 (range 0.301–1). The mean SF-6D for respondents (16414/
64437) who reported having at least one limiting long-term health
condition was 0.6055 (standard error [SE] 0.0011) compared with
0.8104 (SE 0.0006) for respondents who reported no limiting long
term health condition. There were just 2021 respondents who
reported two or more limiting long-term illnesses and 32 sub-
groups (n  30) with two concurrent conditions (see Appendix
or details, found at doi:10.1016/j.jval.2010.12.011). The mean
F-6D scores (Fig. 1) for these subgroups ranged from 0.4648 (SE
0.0086) for respondents (n  140) who reported both a mental
disorder and a musculoskeletal condition to 0.6068 (SE 0.0269)
for respondents (n  33) who reported both arthritis/rheuma-
tism/fibrositis and an unclassifiable complaint. As can be seen
in Figure 1, the SF-6D scores are clustered around the mean
(0.5301) with just 4/32 groups scoring less than 0.50 or greater
than 0.60. When comparing mean SF-6D scores, all scores from
the subgroups with comorbid health conditions were smaller
than those from the subgroups with the corresponding single
health conditions.
The linearmodel estimated using ordinary least squares is pro-
vided in Table 1. The coefficients for all three independent vari-
ables are negative, which would be expected because they are the
decrements associatedwith the health conditions.When compar-
ing the magnitude of the coefficients, the coefficient for the con-
dition with the maximum decrement is larger than the coefficient
for the condition with the minimum decrement as might be ex-
pected. Theweight associatedwith the interaction term (P 0.661)
is similar to that for the health condition with the minimum dis-
utility.
A summary of the results obtained using the five alternative
techniques is provided in Table 2. Overall, the HSUVs obtained
using the linearmodel are themost accurate producing the small-
est MAE (0.0191) and the smallest RMSE (0.0254) in the predicted
mean SF-6D values. Although the average of the predicted mean
SF-6D scores equals the actual value of 0.5301, the range is some-
what truncated (predicted range: 0.4935–0.5549, actual range:
0.4368–0.6068). All predicted HSUVs, however, are within the MID
for the SF-6D and 75% have of the errors are smaller than 0.025.
Of the four nonparametric methods, the ADE outperforms the
other three having the smallest MAE (0.0419) and smallest RMSE
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Fig. 1 – Distribution of mean SF-6D scores for sub(0.0471). When examining accuracy in predicting the individualmean SF-6D scores, the ADE does not compare favorably with the
linear model and only 47% (25%) of estimated HSUVs are accurate
to within the MID ( 0.025 ). The additive, multiplicative and min-
imum methods perform less well with just 3%, 6%, and 13% of
estimated HSUVs within the MID respectively.
Figure 2 shows the actual and estimated mean SF-6D scores.
It is clear that the minimum method overestimates the actual
SF-6D scores and the errors increase as the actual SF-6D scores
decrease. The additive, multiplicative and ADE methods under-
estimate the majority of the actual SF-6D scores. Although the
linear model produces the most accurate scores, there is a ten-
dency for the errors to be larger at the extremes of the range of
actual scores.
When subgrouped by actual SF-6D score (Table 3) it can be seen
that the value of the SF-6D score being estimated can influence the
accuracy of themethods. For example, theminimummethod was
the least accurate in terms of mean errors overall; however, it
performs better than all the other nonparametric methods when
estimating actual SF-6D scores greater than 0.55 and 71% of these
estimated values are accurate to within the MID. Similarly, when
estimating SF-6D scores smaller than 0.50, the ADE produces 86%
of HSUVs accurate to within theMID compared with 57% of values
38%
19%
0%
3%
0.53 0.55 0.58 0.60
ps with two comorbid conditions
ps (n = 32) with two comorbid health conditions.
Table 1 – Results from the OLS combination model.
Independent variable Coefficient Robust SE P  |t|
Maximum decrement 1.049809 0.6162 0.099
Minimum decrement 0.4797101 0.89592 0.597
Interaction of utilities 0.4986031 1.12376 0.661
Constant 1.0606200 0.77913 0.184
R2 0.3472
Maximum decrement maxUnAUA, UnbUB
Minimum decrement minUnAUA, UnbUB
Interaction of utilities UnA, nB · UAUnA · UBUnb%
50
ubgrouOLS, ordinary least square regression; SE, standard error.
743V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 4 0 – 7 4 5predicted using the linear model. The additive method does not
perform well across the full range of actual SF-6D scores whereas
themultiplicativemethod performs better when estimating SF-6D
scores smaller than 0.50.
Discussion
The objective of the studywas to add to the existing evidence base
by comparing the accuracy of methods frequently used to esti-
mate HSUVs for comorbid health conditions. Using SF-6D data
obtained from respondents taking part in Welsh Health Surveys,
we found that the linear model obtained using an OLS regression
out-performed the non-parametric methods. Overall, 88% of
HSUVs predicted using the linear model were within the MID of
the SF-6D. The additive method underestimated the actual SF-6D
scores and produced some substantial errors with none of the
estimated HSUVswithin theMID for the SF-6D. Although themin-
imummethod overestimated the actual HSUVs, it performed bet-
ter when estimating SF-6D scores greater than 0.55 with errors in
estimated values increasing as actual SF-6D scores decreased. The
multiplicative and ADE methods both underestimated the major-
ity of the actual SF-6D scores. However, when looking at sub-
groups of actual SF-6D scores, both methods both performed bet-
ter when estimating SF-6D scores greater than 0.50 with 43% and
Table 2 – Comparing the predictive abilities of the four me
Actual
Additive Multiplic
Mean SF-6D 0.5301 0.4092 0.455
Min SF-6D 0.4368 0.3453 0.411
Max SF-6D 0.6068 0.4794 0.507
Range 0.1700 0.1341 0.096
Mean error 0.1209 0.074
Maximum absolute error 0.1924 0.149
MAE 0.1209 0.074
MSE 0.0157 0.006
RMSE 0.1252 0.079
Proportion within |0.01| 0% 3%
Proportion within |0.025| 0% 6%
Proportion within MID |0.041| 3% 6%
ADE, adjusted decrement estimator; MAE, mean absolute errors; MID
mean squared error.
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Fig. 2 – Plot of the actual and estimated SF-6D scores. ADE, a
regression.86% of estimated HSUVs accurate to within the MID for the multi-
plicative and ADE, respectively.
Our findings are similar to those reported in a recent publica-
tion using EQ-5D data obtained from the MEPS [8]. The range in
actual HSUVs for the comorbid health conditions ranged from 0.62
to 0.88 and the authors reported the ADEmodel outperformed the
additive, minimum, and multiplicative methods when assessed
byMEs and RMSE in estimated values. Charts of the estimated and
actual EQ-5D scores showed the additive andmultiplicativemeth-
ods underestimated the actual EQ-5D scores and themagnitude of
errors increased as the actual EQ-5D score increased for both
methods. As in our data, the minimum method performed better
for higher HSUVs with the magnitude of errors increasing as the
actual HSUV decreased. Although the ADE performed better than
the other methods overall, the magnitude of errors in estimated
values grew substantially as the actual EQ-5D score decreased.
There are three limitations relating to the data used in the
current study. First, the range in actual mean SF-6D scores
(0.4648–0.6068) for the comorbid health conditions covered only
24% of the possible range (0.29–1) and all values were in the bot-
tom half of the SF-6D index (i.e.,  0.65). Actual mean HSUVs for
comorbid health conditions reported in other studies tend to be in
the upper range of the preference based indices. For example, Hu
and Fu [8] used data from MEPS and their actual EQ-5D scores
s [8].
Estimated
e Minimum ADE (Hu) Linear model
0.5848 0.4918 0.5301
0.5620 0.4656 0.4935
0.6053 0.5169 0.5549
0.0433 0.0513 0.0614
0.0546 0.0383 0.0000
0.1316 0.1196 0.0669
0.0563 0.0419 0.0191
0.0038 0.0022 0.0006
0.0613 0.0471 0.0254
0% 0% 31%
6% 25% 75%
13% 47% 88%
imum important difference; MSE, mean squared errors; RMSE, root
Actual
Additive
Multiplicative
Minimum
OLS Combination
ADE
ted decrement estimator; OLS, ordinary least squarethod
ativ
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744 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 4 0 – 7 4 5ranged from 0.62 to 0.88 which equates to 24% of the possible
range (0.1–1) for the US EQ-5D index [7,8,22], Janssen [6] used a
imilar dataset and reported actual mean EQ-5D scores for comor-
id health conditions ranging from 0.734 to 0.819 [6]. The widest
ange (0.01–1) of actual mean HSUVs for comorbid conditions
as reported in a dataset of HUI3 scores obtained from the Cana-
ian Community Health Survey (2001, 2003). However, the major-
ty (184/278) of scores were greater than 0.80. One possible expla-
ation for the differences in the ranges for the actual HSUVs is that
he respondents in our dataset were asked to identify limiting
ong-standing illnesses, while the respondents in the surveys for
he other studieswere asked to identify chronic health conditions.
he consequence of this is that the respondents in the WHS may
ot have reported health conditions they did not perceive to affect
heir HRQoL. As the accuracy in the estimating methods has been
hown to vary depending on the range of the scores estimated in
oth this study and Hu’s [8], it is possible that different conclu-
ions would be drawn if the methods were tested in datasets that
overed the full ranges of the indices.
Second, we were only able to identify 32 subgroups with co-
orbid health conditions and the number of cases in some of the
ubgroups was relatively small (n 30–346). As a consequence we
did not estimate HSUVs for comorbid health conditions consisting
of greater than two health conditions. Although Flanagan et al. [5]
assessed the accuracy of the multiplicative method in estimating
HSUVs for comorbid health conditions consisting of more than
two health conditions, as far as we are aware, this is the only
research in this area and no one has compared results formultiple
comorbid health conditions using alternative methods to date.
Third, although we obtained a linear model to predict SF-6D
scores for the comorbid health conditions, the number of cases
used in the regression was small (n  32) and none of the coeffi-
cients in the model were statistically significant. As the model
tends to over predict the lower SF-6D scores and under predict the
higher SF-6D scores it is possible that a different model specifica-
tion would producemore accurate results and additional research
exploring alternatives is warranted.
It should be noted that in terms of both goodness of fit and
predictive strength, the results vary a lot by baseline SF-6D score.
Our results may not generalize to all other preference-based in-
struments and datasets, and the observed hierarchy of the five
methods is equivalent to that reported in an article describing
similar research on EQ-5D data [23]. One area where additional
research would be particularly informative would be in evaluating
Table 3 – Errors in estimated HSUVs subgrouped by actual
Actual SF-6D score n Additive Mu
Mean error
SF-6D  0.55 7 0.1399
0.55  SF-6D  0.50 18 0.1271
SF-6D  0.50 7 0.1105
Mean absolute error
SF-6D  0.55 7 0.1399
0.55  SF-6D  0.50 18 0.1271
SF-6D  0.50 7 0.1105
Root mean squared error
SF-6D  0.55 7 0.1430
0.55  SF-6D  0.50 18 0.1302
SF-6D  0.50 7 0.1172
Accurate to within the |MID|
SF-6D  0.55 7 0%
0.55  SF-6D  0.50 18 0%
SF-6D  0.50 7 14%
ADE, adjusted decrement estimator; HSUVs, health state utility valuethe different techniques on subgroups of combinations of specifichealth conditions. For example the fivemethodsmay produce dif-
ferent levels of accuracy when combining data from single health
conditions which have a substantial effect on mental health di-
mensions compared to when combining data from single health
conditions which have a substantial effect on physical health di-
mensions. In addition, research exploring the most appropriate
method when combining data for acute and chronic conditions
would also be relevant.
Conclusion
Despite the limitations in the data, this studymakes an important
contribution to the evidence base. This study compared the five
different techniques on SF-6D data and, although the range of
estimated scores was relatively small, it covered the lower end of
the preference based indexwhereas themajority of other research
in this area has involved actual HSUVs at the top end of the pref-
erence measures. Although the linear model gave the most accu-
rate results in our sample, additional research is required to de-
velop and validate the model.
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